Literature DB >> 7718872

Characterization of CD33 as a new member of the sialoadhesin family of cellular interaction molecules.

S D Freeman1, S Kelm, E K Barber, P R Crocker.   

Abstract

CD33 is a member of the Ig superfamily that is restricted to cells of the myelomonocytic lineage but whose functions and binding properties are unknown. It shares sequence similarity with sialoadhesin, CD22, and the myelin-associated glycoprotein, which constitute the Sialoadhesin family of sialic acid-dependent cell adhesion molecules. In the present study, we show that CD33 is a fourth member of this family. As a model for sialic acid-dependent binding, human erythrocytes were derivatized with N-acetylneuraminic acid (NeuAc) in different linkages. A recombinant soluble form of CD33, Fc-CD33, bound red blood cells with a specificity similar to that of sialoadhesin, preferring NeuAc alpha 2,3Gal in N- and O-glycans over NeuAc alpha 2,6Gal in N-glycans. Fc-CD33 also bound selectively to the myeloid cell lines HL-60 and U937. However, CD33 was unable to mediate cell binding after transient expression in COS cells, despite high levels of surface expression. Pretreatment of the CD33-transfected cells with sialidase rendered them capable of mediating sialic acid-dependent binding. These results show that CD33 can function as a sialic acid-dependent cell adhesion molecule and that binding can be modulated by endogenous sialoglycoconjugates when CD33 is expressed in a plasma membrane.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7718872

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  60 in total

1.  Identification, characterization and leucocyte expression of Siglec-10, a novel human sialic acid-binding receptor.

Authors:  J Munday; S Kerr; J Ni; A L Cornish; J Q Zhang; G Nicoll; H Floyd; M G Mattei; P Moore; D Liu; P R Crocker
Journal:  Biochem J       Date:  2001-04-15       Impact factor: 3.857

Review 2.  Siglecs in the immune system.

Authors:  P R Crocker; A Varki
Journal:  Immunology       Date:  2001-06       Impact factor: 7.397

Review 3.  Multifarious roles of sialic acids in immunity.

Authors:  Ajit Varki; Pascal Gagneux
Journal:  Ann N Y Acad Sci       Date:  2012-04       Impact factor: 5.691

Review 4.  LFA-1 on leukemic cells as a target for therapy or drug delivery.

Authors:  Rungsinee Phongpradist; Chuda Chittasupho; Siriporn Okonogi; Teruna Siahaan; Songyot Anuchapreeda; Chadarat Ampasavate; Cory Berkland
Journal:  Curr Pharm Des       Date:  2010-07       Impact factor: 3.116

Review 5.  Evolution of CD33-related siglecs: regulating host immune functions and escaping pathogen exploitation?

Authors:  Huan Cao; Paul R Crocker
Journal:  Immunology       Date:  2010-11-11       Impact factor: 7.397

6.  Human-specific derived alleles of CD33 and other genes protect against postreproductive cognitive decline.

Authors:  Flavio Schwarz; Stevan A Springer; Tasha K Altheide; Nissi M Varki; Pascal Gagneux; Ajit Varki
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-30       Impact factor: 11.205

Review 7.  Siglecs as sensors of self in innate and adaptive immune responses.

Authors:  James C Paulson; Matthew S Macauley; Norihito Kawasaki
Journal:  Ann N Y Acad Sci       Date:  2012-01-30       Impact factor: 5.691

8.  Surface expression and function of p75/AIRM-1 or CD33 in acute myeloid leukemias: engagement of CD33 induces apoptosis of leukemic cells.

Authors:  C Vitale; C Romagnani; A Puccetti; D Olive; R Costello; L Chiossone; A Pitto; A Bacigalupo; L Moretta; M C Mingari
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-24       Impact factor: 11.205

Review 9.  Basic and clinical immunology of Siglecs.

Authors:  Stephan von Gunten; Bruce S Bochner
Journal:  Ann N Y Acad Sci       Date:  2008-11       Impact factor: 5.691

Review 10.  Molecularly targeted therapies for pediatric acute myeloid leukemia: progress to date.

Authors:  Patrick Brown; Franklin O Smith
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.